Vectans Pharma is an international pharmaceutical company bringing a new therapeutic approach with its Lauriad® technology born of French R&D.
This innovative technology enables targeted and prolonged diffusion of APIs, thus optimizing effectiveness and compliance for the benefit of patients.
Vectans Pharma's portfolio currently comprises two products, Sitavig® and Loramyc®, both market-approved by American (FDA), European (EMA) and Japanese (PMDA) health authorities.
Through international licensing agreements, Loramyc®; is commercialized in the United States, Japan, Italy and France, and Sitavig®; in the United States and France.
